RT Journal Article
SR Electronic
T1 Potentially inappropriate prescribing of DOACs to people with mechanical heart valves: a federated analysis of 57.9 million patients’ primary care records in situ using OpenSAFELY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.27.21261136
DO 10.1101/2021.07.27.21261136
A1 The OpenSAFELY Collaborative
A1 Fisher, Louis
A1 Speed, Victoria
A1 Curtis, Helen J
A1 Rentsch, Christopher T
A1 Wong, Angel YS
A1 Schultze, Anna
A1 Massey, Jon
A1 Inglesby, Peter
A1 Morton, Caroline E
A1 Wood, Marion
A1 Walker, Alex J
A1 Morley, Jessica
A1 Mehrkar, Amir
A1 Bacon, Seb
A1 Hickman, George
A1 Bates, Chris
A1 Croker, Richard
A1 Evans, David
A1 Ward, Tom
A1 Cockburn, Jonathan
A1 Davy, Simon
A1 Bhaskaran, Krishnan
A1 Smith, Becky
A1 Williamson, Elizabeth
A1 Hulme, William
A1 Green, Amelia
A1 McDonald, Helen I
A1 Mathur, Rohini
A1 Eggo, Rosalind M
A1 Wing, Kevin
A1 Forbes, Harriet
A1 Tazare, John
A1 Parry, John
A1 Hester, Frank
A1 Harper, Sam
A1 Meadows, Jonathan
A1 O’Hanlon, Shaun
A1 Eavis, Alex
A1 Jarvis, Richard
A1 Avramov, Dima
A1 Griffiths, Paul
A1 Fowles, Aaron
A1 Parkes, Nasreen
A1 Douglas, Ian J
A1 Evans, Stephen JW
A1 Tomlinson, Laurie
A1 MacKenna, Brian
A1 Smeeth, Liam
A1 Goldacre, Ben
YR 2021
UL http://medrxiv.org/content/early/2021/07/29/2021.07.27.21261136.abstract
AB National guidance was issued during the COVID-19 pandemic to switch patients on warfarin to direct oral anticoagulants (DOACs) where appropriate as these require less frequent blood testing. DOACs are not recommended for patients with mechanical heart valves. We conducted a retrospective cohort study of DOAC prescribing in people with a record of a mechanical heart valve between September 2019 and May 2021, and describe the characteristics of this population. We identified 15,457 individuals with a mechanical heart valve recorded in their records, of whom 1058 (6.8%) had been prescribed a DOAC during the study period. 767 individuals with a record of a mechanical heart valve were currently prescribed a DOAC as of May 31st 2021. This is suggestive of inappropriate prescribing of DOACs in individuals with mechanical heart valves. Direct alerts have been issued to clinicians through their EHR software informing the issue. We show that the OpenSAFELY platform can be used for rapid audit and feedback to mitigate the indirect health impacts of COVID-19 on the NHS. We will monitor changes in prescribing for this risk group over the following months.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: over the past five years BG has received research funding from the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK (HDRUK), the Health Foundation, and the World Health Organisation; he also receives personal income from speaking and writing for lay audiences on the misuse of science. BMK is also employed by NHS England working on medicines policy and clinical lead for primary care medicines data. KB holds a Sir Henry Dale fellowship jointly funded by Wellcome and the Royal Society (107731/Z/15/Z). HIM is funded by the NIHR Health Protection Research Unit in Immunisation, a partnership between Public Health England and London School of Hygiene & Tropical Medicine. AYSW holds a fellowship from the British Heart Foundation. EJW holds grants from MRC. RM holds a Sir Henry Wellcome Fellowship funded by the Wellcome Trust (201375/Z/16/Z). HF holds a UKRI fellowship. IJD has received unrestricted research grants and holds shares in GlaxoSmithKline (GSK).Funding StatementThis work was supported by the Medical Research Council MR/V015737/1 and the Longitudinal Health and Wellbeing strand of the National Core Studies programme. EMIS and TPP provided technical expertise and infrastructure within their data environments pro bono in the context of a national emergency. The OpenSAFELY software platform is supported by a Wellcome Discretionary Award. BG's work on clinical informatics is supported by the NIHR Oxford Biomedical Research Centre and the NIHR Applied Research Collaboration Oxford and Thames Valley. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, Public Health England or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were linked, stored, and analysed securely within the OpenSAFELY platform. Detailed pseudonymised patient data are potentially re-identifiable and therefore not shared. We rapidly delivered the OpenSAFELY data analysis platform without previous funding to deliver timely analyses of urgent research questions in the context of the global COVID-19 health emergency: now that the platform is established, we have established a process for external users to request access to the platform https://www.opensafely.org/onboarding-new-users/.